Dicaffeoylquinic acid (hereinafter referred to as IBE-5) was jointly developed by the Chinese Academy of Military Medical Sciences and Jiangzhong Group. The two parties announced at a press conference held in Nanchang on the 30th that the State Food and Drug Administration has approved IBE-5 to enter the human clinical trial stage. The drug has previously undergone rigorous animal pharmacodynamics and safety tests. The new anti-AIDS drug IBE-5 is a monomer active ingredient screened from plants. In order to facilitate production, an artificial chemical synthesis production process is adopted. Its efficacy and synthesis process have applied for patents in many countries around the world. The new anti-AIDS drug IBE-5 is in HIV-infected MT4 cells can significantly inhibit viral replication, and its effect is significantly stronger than the cocktail therapy drug currently recognized as a better treatment for AIDS in the world.